Zevra Therapeutics to Present at the Citizens Life Sciences Conference

Core Viewpoint - Zevra Therapeutics, Inc. is actively engaging with investors and stakeholders by presenting at the Citizens Life Sciences Conference, highlighting its commitment to rare disease therapies and corporate transparency [1][2]. Company Overview - Zevra Therapeutics is a commercial-stage company focused on developing therapies for rare diseases, specifically its lead product for Niemann-Pick disease type C (NPC), a rare neurodegenerative disorder [3]. - The company emphasizes a patient-centric approach and aims to create long-term value for patients, partners, and shareholders through its values of accountability, integrity, innovation, and courage [3]. Conference Participation - Members of Zevra's executive leadership team will present at the Citizens Life Sciences Conference on March 11, 2026, at 9:00 a.m. ET, indicating the company's proactive approach in engaging with the investment community [1]. - Management will also be available for one-on-one meetings with registered attendees, further enhancing investor relations [2]. Digital Presence - A live webcast of the conference presentation will be available on Zevra's Investor Relations website, showcasing the company's commitment to transparency and accessibility for investors [2].